Home ›
Non-Small Cell (NSCLC) Lung Cancer Trials ›
NCT07890714
A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]
This clinical trial is designed to assess the safety, tolerability, and antitumor activity of Datopotamab Deruxtecan (Dato-DXd) combined with other anticancer agents or as monotherapy in participants with solid tumors.
Trial Details
NCT ID NCT07890714
Phase PHASE1 / PHASE2
Sponsor Daiichi Sankyo
Status RECRUITING
Cancer Type Non-Small Cell (NSCLC) Lung Cancer
Interventions Dato-DXd Enfortumab Vedotin (EV) Pembrolizumab Olomorasib
Locations (sample) Taichung, Taiwan|24.1469,120.6839
Key Eligibility Criteria
Must consent to provide archival tumor tissue sample or newly obtained pretreatment biopsy if clinically feasible and at an acceptable risk as dete… Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1 assessed no more than 14 days prior to Cycle 1 Day 1 (C1D1) (rand… Has adequate organ and bone marrow function as assessed by local laboratory within 7 days prior to C1D1 (randomization for randomized cohort) as de… Has a left ventricular ejection fraction (LVEF) ≥50 percent (%) by either an echocardiogram (ECHO) or multigated acquisition scan (MUGA) scan withi…
For full eligibility, visit ClinicalTrials.gov .